文献速递贫血与红细胞疾病

红细胞生成产生的完整FGF23通过旁分泌抑制红系造血

Erythroid-produced intact FGF23 is a paracrine inhibitor of erythropoiesis.
PubMed 文献 · Blood · 2026-01-01

该研究在小鼠模型中区分了骨细胞与红系细胞来源的FGF23在缺铁性贫血中的作用。红系特异性敲除Fgf23可纠正缺铁小鼠贫血,而过表达则诱导对照小鼠贫血;红系Furin敲除增加完整FGF23产生并加重贫血。完整FGF23通过FGFR1抑制红系祖细胞分化,红系特异性敲除Fgf23可预防慢性肾病贫血。

要点

  • 红系来源的完整FGF23是红系造血的负调控因子
  • 完整FGF23通过激活FGFR1抑制红系祖细胞分化
  • 红系特异性敲除Fgf23可改善缺铁及慢性肾病贫血

核心结论

  • 红系表达的FGF23通过旁分泌FGFR1激活直接抑制红系祖细胞分化,从而促进贫血。

研究设计与样本

  • 使用骨细胞特异性(Fgf23Dmp1-cKO)和红系特异性(Fgf23HbB-cKO)Fgf23敲除小鼠,喂食对照或缺铁饮食。
  • 构建红系特异性Furin敲除小鼠(FurinHbB-cKO)及进展性慢性肾病动物模型。

主要发现

  • 缺铁时骨细胞和红系细胞分别是循环完整FGF23和FGF23裂解肽段的来源。
  • 红系特异性敲除Fgf23纠正缺铁小鼠贫血,而过表达诱导对照小鼠贫血。
  • 红系特异性敲除Furin增加红系产生完整FGF23并加重缺铁诱导的贫血。
  • 完整FGF23剂量依赖性阻断红系祖细胞分化,引发线粒体功能障碍,FGFR1抑制剂可完全抑制这些效应。
  • 在进展性慢性肾病模型中,红系特异性敲除Fgf23预防贫血发生。

临床怎么用

  • 红系来源的完整FGF23可作为缺铁性贫血和慢性肾病贫血的潜在治疗靶点。
  • FGFR1抑制剂可能逆转完整FGF23对红系造血的抑制作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast growth factor 23 (FGF23) is a phosphate-regulating hormone produced by osteocytes. In iron deficiency anemia (IDA) and chronic kidney disease (CKD), FGF23 is also produced by erythroid cells. Recent studies have suggested that rising circulating FGF23 is negatively associated with erythropoiesis in IDA and CKD. However, the distinct contributions of bone- and erythroid-produced FGF23 to anemia in IDA remain unclear. Using the conditional deletion of Fgf23 in osteocytes (Fgf23Dmp1-cKO) and in erythroid cells (Fgf23HbB-cKO) in mice fed a control or an iron-deficient (ID) diet, we first determined that in iron deficiency, osteocytes and erythroid cells are distinct sources of circulating intact FGF23 (iFGF23) and FGF23-cleaved peptides, respectively. We further showed that erythroid-specific deletion of Fgf23 corrected anemia in ID mice, whereas overexpression induced anemia in control mice, unlike osteocyte-specific deletion or overexpression of Fgf23. Importantly, erythroid-specific deletion of Furin (FurinHbB-cKO), the enzyme responsible for FGF23 cleavage, led to the increased production of iFGF23 from erythroid cells and aggravated ID-induced anemia. Furthermore, iFGF23 dose-dependently blocked the differentiation of erythroid progenitors in culture, triggering mitochondrial dysfunction that led to impaired erythropoiesis. These effects were fully suppressed by cotreatment with an FGFR1 inhibitor. Finally, erythroid-specific deletion of Fgf23 in an animal model of progressive CKD prevented the development of anemia of CKD. Collectively, our results show that erythroid-expressed FGF23 is a negative regulator of erythropoiesis that contributes to anemia via direct paracrine FGFR1 activation in erythroid precursors.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Courbon G, Thomas JJ, Duque EJ, et al. Erythroid-produced intact FGF23 is a paracrine inhibitor of erythropoiesis. Blood. 2026. PMID: 42013007. doi:10.1182/blood.2025030634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。